Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EPS (Weighted Average and Diluted): 2010-2024

Historic EPS (Weighted Average and Diluted) for OptimizeRx (OPRX) over the last 13 years, with FY2024 value amounting to -$1.1.

  • OptimizeRx's EPS (Weighted Average and Diluted) rose 10800.0% to $0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.04, marking a year-over-year increase of 10800.0%. This contributed to the annual value of -$1.1 for FY2024, which is 679.61% down from last year.
  • As of FY2024, OptimizeRx's EPS (Weighted Average and Diluted) stood at -$1.1, which was down 679.61% from -$1.03 recorded in FY2023.
  • In the past 5 years, OptimizeRx's EPS (Weighted Average and Diluted) registered a high of $0.02 during FY2021, and its lowest value of -$1.1 during FY2024.
  • In the last 5 years, OptimizeRx's EPS (Weighted Average and Diluted) had a median value of -$0.64 in 2022 and averaged -$0.58.
  • In the last 5 years, OptimizeRx's EPS (Weighted Average and Diluted) surged by 11333.33% in 2021 and then tumbled by 330000.0% in 2022.
  • Annual analysis of 5 years shows OptimizeRx's EPS (Weighted Average and Diluted) stood at -$0.15 in 2020, then skyrocketed by 113.33% to $0.02 in 2021, then crashed by 3300.0% to -$0.64 in 2022, then tumbled by 60.94% to -$1.03 in 2023, then decreased by 6.8% to -$1.1 in 2024.
  • Its EPS (Weighted Average and Diluted) was -$1.1 in FY2024, compared to -$1.03 in FY2023 and -$0.64 in FY2022.